Evidence map›Paper›PMID 31828041›Full record

ArticleFrontiers in oncology2019

Genomic Profiling Reveals Synchronous Bilateral Lung Adenocarcinomas With Distinct Driver Alterations of

Benxu Tan, Xuan Jiang, Ruping Wang, Cuiping Tang, Sisi Liu, Xue Wu, Lei Xia, Xian Yu, Zhenzhou Yang

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Benxu TanDepartment of Oncology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Xuan JiangDepartment of Oncology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Ruping WangDepartment of Research and Development, Nanjing Geneseeq Technology Inc., Nanjing, China.
Cuiping TangDepartment of Oncology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Sisi LiuDepartment of Research and Development, Nanjing Geneseeq Technology Inc., Nanjing, China.
Xue WuTranslational Medicine Research Institute, Geneseeq Technology Inc., Toronto, ON, Canada.
Lei XiaDepartment of Oncology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Xian YuDepartment of Oncology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Zhenzhou YangDepartment of Oncology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Chongqing Medical University · CNSecond Affiliated Hospital of Chongqing Medical University · CNDalian Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

bilateral lung adenocarcinomasEML4-ALKnext-generation sequencingsynchronous multiple primary lung cancersTPM3-ROS1

Identifiers

PMID31828041
PMCPMC6890554
OpenAlexW2990022447

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.